Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex Syringe
NCT00915577 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 74
Last updated 2009-06-08
Summary
Determine patient satisfaction with the single-use autoinjector for the delivery of pre-filled Avonex syringe.
Conditions
Interventions
- DRUG
-
Interferon beta-1a
30mcg, IM once-a-week
- DEVICE
-
Single-use autoinjector
Single-use autoinjector with Avonex 30mcg pre-filled syringe
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Biogen-Idec Investigator · Biogen
Study Design
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2005-08-31
- Primary Completion
- 2006-04-30
- Completion
- 2006-04-30
More Related Trials
-
Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients
NCT00784836 ·Status: TERMINATED ·Phase: PHASE3
-
Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis
NCT00037102 ·Status: COMPLETED ·Phase: PHASE4
-
Canadian Avonex PEN Productivity Study
NCT01489748 ·Status: COMPLETED
-
Open-Label Safety Extension Study of Avonex
NCT00915460 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Interferon Beta-1a (Avonex®) on Changes of Non-conventional MRI Measures in Patients With MS
NCT00463710 ·Status: COMPLETED
-
Peginterferon Beta-1a (BIIB017) Autoinjector Pharmacokinetic Study in Healthy Volunteers
NCT01610310 ·Status: COMPLETED ·Phase: PHASE1
-
Avonex 15 Year Long Term Follow-up Study
NCT00525343 ·Status: COMPLETED
-
Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple Sclerosis
NCT00223301 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
The Multicenter, Open-label, Single-use Autoinjector Convenience Study
NCT00958009 ·Status: COMPLETED ·Phase: PHASE3
-
A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis
NCT03347370 ·Status: COMPLETED
-
Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis
NCT00599274 ·Status: COMPLETED
-
Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy
NCT00493077 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS)
NCT00292266 ·Status: COMPLETED ·Phase: PHASE3
-
Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a?
NCT00534261 ·Status: COMPLETED ·Phase: PHASE4
-
Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS
NCT00168766 ·Status: COMPLETED ·Phase: PHASE4
-
Persistence, Adherence, Quality of Life, and Treatment Satisfaction With Avonex® PEN™.
NCT01405872 ·Status: COMPLETED
-
Evaluation of Brain Atrophy in CIS Patients on Avonex
NCT01592474 ·Status: COMPLETED
-
Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis
NCT00324506 ·Status: COMPLETED ·Phase: PHASE2
-
Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis
NCT00179478 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)
NCT00986960 ·Status: WITHDRAWN ·Phase: PHASE2
-
Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.
NCT00037115 ·Status: WITHDRAWN ·Phase: PHASE4
-
Open, Multicentric, Prospective, Quality of Life Study in Multiple Sclerosis Patients
NCT00928967 ·Status: COMPLETED
-
A Multicenter, Open-label, RebiSmart™ Autoinjector Ease of Use Study
NCT01036165 ·Status: COMPLETED ·Phase: PHASE3
-
Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study
NCT03134573 ·Status: COMPLETED
-
A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
NCT01975298 ·Status: WITHDRAWN ·Phase: PHASE3